Emisphere’s Eligen(R) Technology Demonstrates Delivery Of Active Recombinant Human Growth Hormone (Medical News Today)
Emisphere’s Eligen(R) Technology Demonstrates Delivery Of Active Recombinant Human Growth Hormone (Medical News Today)
Emisphere Technologies, Inc. (”Emisphere”) (Nasdaq: EMIS) announced today that Novartis Pharma AG has notified Emisphere of new Phase I data indicating that recombinant human growth hormone (rhGH) can be absorbed when given to growth hormone-deficient (GHD) patients in a prototype oral formulationusing Emisphere’s eligen(R) delivery technology. [click link for full article]